Incyte | INCY - Operating Expenses

Stock Price
103.16
Daily Change
2.24 2.22%
Monthly
1.35%
Yearly
37.07%
Q1 Forecast
96.99

Incyte reported $4.65B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Exelixis USD 341.4M 13.29M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025